Stock PHRX PHARMADRUG INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pharmadrug Inc.

Equities

PHRX

CA71716W2040

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 11:36:57 2024-05-16 EDT 		5-day change 1st Jan Change
0.035 CAD 0.00% Intraday chart for Pharmadrug Inc. +16.67% -36.36%
05-15 PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine MT
05-01 PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7.768 2.083 15.76 11.93 5.334 4.809
Enterprise Value (EV) 1 8.573 5.131 12.48 11.5 6.428 6.153
P/E ratio -0.88 x -0.28 x -2.18 x -2.06 x -0.59 x -0.24 x
Yield - - - - - -
Capitalization / Revenue - 3,410,806 x 23,052,644 x 24,098,557 x - -
EV / Revenue - 8,403,103 x 18,257,159 x 23,231,869 x - -
EV / EBITDA - -1,196,159 x -4,906,403 x -3,003,751 x -3,616,747 x -4,608,775 x
EV / FCF -8.2 x -4.18 x -10.2 x -7.4 x -6.3 x 3.6 x
FCF Yield -12.2% -23.9% -9.82% -13.5% -15.9% 27.7%
Price to Book -15.8 x 0.7 x 2.07 x 0.71 x 0.6 x -2.84 x
Nbr of stocks (in thousands) 4,439 11,900 28,144 48,688 50,804 87,437
Reference price 2 1.750 0.1750 0.5600 0.2450 0.1050 0.0550
Announcement Date 4/30/19 6/15/20 4/30/21 5/3/22 5/12/23 4/30/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 0.6106 0.6837 0.495 - -
EBITDA - -4.289 -2.544 -3.828 -1.777 -1.335
EBIT 1 -0.9299 -5.041 -3.799 -5.047 -2.356 -1.361
Operating Margin - -825.6% -555.69% -1,019.59% - -
Earnings before Tax (EBT) 1 -3.512 -6.982 -5.903 -6.707 -3.254 -14.27
Net income 1 -3.886 -6.29 -5.219 -5.626 -8.876 -13.2
Net margin - -1,030.15% -763.38% -1,136.69% - -
EPS 2 -1.978 -0.6280 -0.2565 -0.1189 -0.1790 -0.2340
Free Cash Flow 1 -1.046 -1.227 -1.226 -1.554 -1.02 1.707
FCF margin - -200.9% -179.38% -313.92% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/19 6/15/20 4/30/21 5/3/22 5/12/23 4/30/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.81 3.05 - - 1.09 1.34
Net Cash position 1 - - 3.28 0.43 - -
Leverage (Debt/EBITDA) - -0.7106 x - - -0.6152 x -1.007 x
Free Cash Flow 1 -1.05 -1.23 -1.23 -1.55 -1.02 1.71
ROE (net income / shareholders' equity) 620% -330% -73.4% -42.3% -23.8% -360%
ROA (Net income/ Total Assets) -58.1% -55.1% -19.7% -19% -9.31% -12.8%
Assets 1 6.683 11.42 26.45 29.62 95.35 103.3
Book Value Per Share 2 -0.1100 0.2500 0.2700 0.3500 0.1700 -0.0200
Cash Flow per Share 2 0.0300 0.0100 0.0600 0.0200 0 0
Capex - 0.01 0.02 - - -
Capex / Sales - 1.6% 2.63% - - -
Announcement Date 4/30/19 6/15/20 4/30/21 5/3/22 5/12/23 4/30/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
PHARMADRUG INC. Stock Pharmadrug Inc.
-36.36% 2.69M
MCKESSON CORPORATION Stock McKesson Corporation
+20.04% 71.69B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-2.10% 23.65B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+9.05% 9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+10.34% 8.64B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-19.68% 8.15B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+13.68% 5.33B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+14.69% 4.35B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.04% 4.1B
GALENICA AG Stock Galenica AG
-2.27% 3.94B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. PHRX Stock
  4. Financials Pharmadrug Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW